Medical/Pharmaceuticals
NMPA accepted the registration applications for Uro-G and Uro-3500
SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the registration applications for ...
2023-02-21 17:46
2744
RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore
SINGAPORE, Feb. 20, 2023 /PRNewswire/ -- RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immuno...
2023-02-21 10:00
2787
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis
* BBT-401 meets safety endpoints achieved in previous clinical studies * The drug candidate did not achieve an improved clinical response compared to the placebo study group * 54.5% of the treatment cohort exhibited a valid treatment response to orally administered BBT-401 SEONGNAM, South Ko...
2023-02-21 07:00
2639
EDAN Pictured the Long-Term Regional Development Plans with the Minister Counselor of the Chinese Embassy in Kenya
NAIROBI, Kenya, Feb. 20, 2023 /PRNewswire/ -- Minister Counselor of the Chinese Embassy inKenya, Yijun Zhang held a meeting on February 7, 2023 with Alex You, Global Marketing & Strategic Operations Director, andVincent Bi, Customer Service & Healthcare Informatics Director ofEdan Instruments, In...
2023-02-21 00:15
3505
MINDLAX REVOLUTIONIZES SLEEP SOLUTIONS WITH VIBROACOUSTIC SLEEPING MAT
The MindLax Sleeping Mat uses tactile-aural mechanisms that trigger the body's natural processes to induce relaxation and aid better sleep COLORADO SPRINGS, Colo., Feb. 20, 2023 /PRNewswire/ -- MindLax, the leading innovator in natural sleep and relaxation products and maker of the MindLax Sleep...
2023-02-21 00:00
3349
Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease
* Co-research and co-development of novel microbiome therapeutics * Discovery of new candidates to meet high unmet medical needs in Parkinson's disease SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ -- LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology...
2023-02-20 22:00
3192
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 19, 2023 /PRNewswire/ ...
2023-02-20 12:29
2934
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
YONGIN, South Korea, Feb. 19, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has granted prequalification for BARYCELA, GC Biopharma's varicella vaccine. WHO prequalificatio...
2023-02-20 09:38
2837
Lunit to Establish Subsidiary in Europe to Accelerate Business Expansion
* Lunit to establish new subsidiary, Lunit Europe Holdings, to expand sales network acrossEurope and strengthen global capabilities SEOUL, South Korea, Feb. 17, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer solutions, today announced its decision to establis...
2023-02-17 21:12
4950
Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders
JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (the "Company" or Nasdaq: QLI), aChina-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of$0.05 per ordinary share, payable i...
2023-02-17 05:30
4335
Terumo Blood and Cell Technologies' IMUGARD Platelet Pooling Set Cleared by FDA
IMUGARD to Help Strained U.S. Platelet Supply Meet Growing Need LAKEWOOD, Colo., Feb. 16, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extende...
2023-02-17 03:48
2879
GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
* Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe forNew Zealand patients * YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 16, 2023 /PRNewswire/ -- Independen...
2023-02-17 03:00
3148
111, Inc. Hosts Hua Medicine Launches First Official Flagship Store
SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr.Yu Gang, Co-founder and Executive...
2023-02-16 13:33
2893
WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023
SHANGHAI, Feb. 15, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced today that it ...
2023-02-16 08:00
2724
Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery
Collaboration to develop 3D in vitro models of the brain for the discovery of
therapeutic candidates using Inventia's novel 3D cell culture platform, RASTRUM™
SYDNEY, Feb. 15, 2023 /PRNewswire/ -- February 16, 2023, Inventia Life Science
2023-02-16 06:00
3407
AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider
NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...
2023-02-15 21:00
4435
Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)
Initial Part A results to be presented at the upcoming American Society of Cataract and Refractive Surgery Annual Meeting EB-301 has the potential to be the world's first approved rhCIII biosynthetic corneal implant for the treatment of corneal blindness SUZHOU, China and SAN FRANCISCO, Feb. 14,...
2023-02-15 01:00
2723
Randomized Controlled Trial Backs Clinical Efficacy of Lunit AI for Chest X-Ray
* First-ever randomized controlled trial regarding deep learning-based AI in radiology provides strong evidence for the clinical value of AI * Large-scale study with 10,476 patients published in Radiology, the top journal in radiology SEOUL, South Korea, Feb. 13, 2023 /PRNewswire/ -- Findings ...
2023-02-13 21:00
2905
AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S.
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina announced that on February 12, 2023, the Company, through its subsidiary Foodbase Group Inc., entered into a definitive equity purchas...
2023-02-13 21:00
4626
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023 SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb. 13, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ...
2023-02-13 20:30
3197
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 279 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24436